LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

31.21 -0.03

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

31.2

Massimo

31.23

Metriche Chiave
By Trading Economics
Entrata	11M 64M
Vendite	-3.2M 149M
P/E Media del settore	18.542 51.415
EPS	0.68
Margine di Profitto	42.663
Dipendenti	182
EBITDA	-7.8M 73M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+6.06% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	271M 3.8B
Apertura precedente	31.24
Chiusura precedente	31.21

Notizie sul Sentiment di mercato

By Acuity

50%

174 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 24.28 Supporto e resistenza

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 mag 2026, 20:36 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mag 2026, 23:28 UTC

Discorsi di Mercato

Utili

Global Forex and Fixed Income Roundup: Market Talk

19 mag 2026, 23:28 UTC

Discorsi di Mercato

Utili

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mag 2026, 23:10 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

19 mag 2026, 23:10 UTC

Discorsi di Mercato

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mag 2026, 22:02 UTC

Utili

ZTO Express (Cayman): Di Xu to Resign From Board

19 mag 2026, 22:01 UTC

Utili

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mag 2026, 22:01 UTC

Utili

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mag 2026, 22:00 UTC

Utili

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mag 2026, 21:37 UTC

Utili

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mag 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mag 2026, 21:01 UTC

Utili

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mag 2026, 20:58 UTC

Utili

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mag 2026, 20:46 UTC

Azioni calde

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mag 2026, 20:43 UTC

Discorsi di Mercato

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mag 2026, 20:34 UTC

Utili

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries 4Q EPS 5c >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries 4Q Sales $1.4B >JHX

19 mag 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mag 2026, 20:18 UTC

Discorsi di Mercato

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mag 2026, 20:13 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

19 mag 2026, 20:13 UTC

Discorsi di Mercato

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mag 2026, 20:03 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mag 2026, 20:03 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mag 2026, 20:02 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mag 2026, 20:02 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mag 2026, 19:23 UTC

Discorsi di Mercato

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

6.06% in crescita

Previsioni per 12 mesi

Media 33.1 USD 6.06%

Alto 35 USD

Basso 31.5 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

174 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.